查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1976308

POC脂质检测市场：依产品类型、技术、应用、最终用户和通路划分－2026-2032年全球预测

POC Lipid Testing Market by Product Type, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，即时血脂检测市场价值将达到 3.5486 亿美元，到 2026 年将成长至 3.8186 亿美元，到 2032 年将达到 5.6932 亿美元，年复合成长率为 6.98%。

主要市场统计数据
基准年 2025 3.5486亿美元
预计年份：2026年 3.8186亿美元
预测年份 2032 5.6932亿美元
复合年增长率 (%) 6.98%

简要概述技术进步、临床需求和监管澄清如何重塑照护现场血脂检测的交付模式。

照护现场血脂检测已成为现代化心臟代谢预防保健的关键要素，能够实现更快速的风险评估和更有效率的临床工作流程。检测化学、仪器小型化和介面设计的进步，共同降低了在传统中心检查室之外提供临床实用血脂谱所需的时间和复杂性。因此，临床医生、护理团队和患者现在可以在就诊期间更快地获得三酸甘油酯和胆固醇水平，从而辅助决策。

快速的技术创新、分散的医疗保健模式以及不断变化的医疗保健系统奖励，从根本上改变了照护现场血脂检测的实施和交付方式。

在技​​术创新和不断发展的诊疗路径的驱动下，照护现场脂质诊断的环境正在经历变革性变化。新的检测技术以及日益紧凑的桌上型和携带式分析仪正在缩小与中心检查室平台之间的性能差距，照护现场实现更可靠的床边脂质检测。这些技术进步辅以试剂稳定性的提升和工作流程的简化，减轻了非检查室人员的工作负担。

分析考察了近期关税措施如何重塑了整个照护现场血脂诊断生态系统的供应链策略和采购方式。

美国近期实施的关税措施为照护现场血脂检测设备及耗材的生产商和供应商带来了复杂的经营环境。部分进口诊断组件关税的提高导致依赖全球供应链的营业单位成本上升，促使其重新评估筹资策略和总到岸成本。因此，采购部门更重视供应商多元化和合约保障，以维持利润率并确保产品供应。

基于细分市场的洞察揭示了产品类型、用户环境、技术、通路和临床应用如何共同决定采用趋势。

产品细分研究表明，市场可分为耗材和仪器两大类。耗材包括品管、试剂盒和试剂等关键组件，这些组件决定了检测性能和批间一致性。仪器则包括适用于临床和检查室环境的桌上型分析仪，以及针对速度和便携性进行最佳化的携带式分析仪。消费者购买行为的转变日益凸显了整体拥有成本和检验耗材供应稳定性的重要性，这使得能够确保试剂长期供应并提供简单易用的仪器维护流程的製造商获得了竞争优势。

区域比较分析：说明不同法规结构、基础设施成熟度和支付方环境对照护现场血脂检测部署路径的影响。

区域趋势影响照护现场血脂检测的推广路径和营运策略。在美洲，由于相对成熟的医疗保健体系和健全的私人分销系统，临床网络优先将快速诊断整合到基层医疗和社区诊所中。这种环境促进了桌上型和携带式分析仪的普及，从而提高了工作流程效率并增强了病人参与。此外，诊断检查室的强大基础也为混合推广模式提供了契机，这些模式能够将照护现场平台与中心检查室标准检验。

如何透过检测创新、综合服务模式、策略伙伴关係和严格的临床证据产生来建构竞争优势。

照护现场血脂检测领域的竞争动态是由产品创新、策略联盟和临床检验声明之间错综复杂的相互作用所决定的。主要企业正大力投资于检测方法的开发和易用性工程，以透过准确性、速度和整合能力脱颖而出。随着企业寻求确保原材料供应并降低贸易政策波动带来的风险，与试剂和组件供应商建立供应链合作伙伴关係以及共同开发契约变得越来越普遍。

製造商和医疗保健系统领导者应优先采取策略行动，以增强韧性、加快部署并展现临床和商业性价值。

产业领导者应优先考虑供应链多元化和生产柔软性，以此来规避贸易政策波动和零件短缺的风险。投资建设区域组装基地，并为关键试剂和设备组件选择替代供应商，可显着降低关税和物流波动带来的风险。同时，他们也应评估产品设计，以简化组件的复杂性，并实现高度灵活的生产系统，以及根据需要快速更新法规。

为了支持策略决策，我们采用严格的混合调查方法，结合相关人员访谈、监管审查、设备基准测试和专家检验。

本分析整合了混合方法研究的洞见，结合了对关键产业相关人员的定性访谈以及对监管、临床和专利文献的系统性回顾。主要资讯来源包括与临床实验室负责人、采购经理、医疗设备工程师和支付方的结构化对话，以检验营运挑战和实施标准。这些观点与公开的监管文件、临床试验註册资讯和同行评审出版物进行三角验证，以确保技术和临床的准确性。

简明扼要的总结强调了产品、临床证据和供应链策略的必要整合，以实现照护现场血脂检测的潜力。

照护现场血脂检测正处于转折点，其发展动力源于技术进步、医疗模式向分散化转型以及临床医生和患者不断变化的期望。仪器设计、耗材可靠性和分销策略的相互作用将决定哪些解决方案能够有效应用于各种临床环境。同时，贸易政策和供应链现状的变化​​也要求企业采用更具韧性的商业模式和更务实的生产方式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：即时血脂检测市场：依产品类型划分

  • 消耗品
    • 控制
    • 成套工具
    • 试剂
  • 装置
    • 桌面分析仪
    • 携带式分析设备

第九章：即时血脂检测市场：依技术划分

  • 层析法
  • 比色法
  • 酵素法
  • 免疫检测

第十章：即时血脂检测市场：依应用领域划分

  • 心血管疾病风险评估
  • 糖尿病管理
  • 预防性筛检

第十一章：即时血脂检测市场：依最终用户划分

  • 诊所
  • 诊断检查室
  • 家庭测试
  • 医院

第十二章：即时血脂检测市场：依通路划分

  • 诊断检查室
  • 电子商务
  • 医院药房
  • 零售药房

第十三章：即时血脂检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：即时血脂检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：即时血脂检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国即时血脂检测市场

第十七章：中国即时血脂检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Callegari Srl
  • Chembio Diagnostic Systems, Inc. by BIOSYNEX SA
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd.
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical
  • Quidel Corporation
  • SD Biosensor, Inc.
  • Sekisui Medical Co., Ltd.
  • Siemens AG
  • Sienco, Inc.
  • Sinocare Inc.
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • VivaChek Biotech（Hangzhou）Co., Ltd.
  • Werfen, SA
Product Code: MRR-DD0700E81D15

The POC Lipid Testing Market was valued at USD 354.86 million in 2025 and is projected to grow to USD 381.86 million in 2026, with a CAGR of 6.98%, reaching USD 569.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 354.86 million
Estimated Year [2026] USD 381.86 million
Forecast Year [2032] USD 569.32 million
CAGR (%) 6.98%

A concise overview of how technological advances, clinical demand, and regulatory clarity are reshaping point-of-care lipid testing delivery models

Point-of-care lipid testing has emerged as a pivotal component in modern preventive cardiometabolic care, enabling more immediate risk assessment and streamlined clinical workflows. Advances in assay chemistry, device miniaturization, and interface design have collectively reduced the time and complexity required to deliver clinically actionable lipid profiles outside traditional central laboratories. As a result, clinicians, care teams, and patients now expect faster access to triglyceride and cholesterol metrics that can inform same-encounter decision-making.

Moreover, the convergence of remote monitoring, telehealth, and decentralized diagnostic strategies is reshaping how lipid testing is deployed in ambulatory settings, community clinics, and increasingly within the home. Regulatory authorities have clarified pathways for point-of-care devices while payers and health systems explore reimbursement and value pathways that reflect the potential for earlier intervention and reduced downstream costs. At the same time, laboratory professionals continue to emphasize the need for rigorous quality assurance, method comparability, and robust clinical validation to preserve diagnostic confidence.

Taken together, these dynamics create both opportunity and obligation for manufacturers, distributors, and healthcare providers. Industry players must balance speed-to-market with demonstrable accuracy, user-centric design, and integration capabilities that support electronic health record interoperability and clinical decision support. As adoption grows, stakeholders who proactively address operational, regulatory, and clinical alignment will be best positioned to capitalize on the shift toward more immediate lipid assessment.

How rapid innovation, decentralized care models, and evolving health system incentives are fundamentally altering point-of-care lipid testing adoption and delivery

The landscape for point-of-care lipid diagnostics is experiencing transformative shifts driven by technological innovation and evolving care pathways. New assay modalities and increasingly compact benchtop and handheld analyzers have narrowed the performance gap with central laboratory platforms, enabling more reliable lipid panels at the point of care. These technical gains are complemented by improved reagent stability and streamlined workflow designs that lower the operational burden on non-laboratory personnel.

Simultaneously, the rise of home testing and patient-centered care models has prompted device makers to focus on usability, connectivity, and data security. Vendors are investing in digital ecosystems that link test results to mobile apps and telehealth platforms, which supports shared decision-making between patients and clinicians. In parallel, clinical practice guidelines and payer policies are adapting to recognize the role of rapid lipid assessment in chronic disease management and preventive screening, which influences procurement priorities and deployment strategies.

Supply chain resilience has also become a strategic imperative, with manufacturers diversifying sourcing and considering regional production hubs to mitigate disruptions. As adoption broadens, partnership models are shifting away from one-size-fits-all sales toward outcome-oriented collaborations that offer bundled device-and-service solutions. Consequently, the market is moving toward a more integrated, patient-focused diagnostic paradigm where speed, quality, and interoperability determine long-term value.

An analytical review of how recent tariff measures have reshaped supply chain strategies and procurement approaches across the point-of-care lipid diagnostics ecosystem

Recent tariff measures implemented in the United States have created a complex environment for manufacturers and suppliers of point-of-care lipid testing equipment and consumables. Increased duties on certain imported diagnostic components have amplified costs for entities reliant on global supply chains, prompting organizations to re-evaluate sourcing strategies and total landed costs. As a direct result, procurement teams are placing greater emphasis on supplier diversification and contractual protections to preserve margin and maintain product availability.

In response, some vendors are accelerating discussions around nearshoring and local assembly to reduce exposure to cross-border tariff volatility. These shifts are not solely procurement-driven; they also influence product design choices as companies seek to reduce reliance on tariffed components by redesigning kits and instruments for regional manufacturing compatibility. At the same time, distributors and healthcare providers are responding by negotiating longer-term agreements and inventory buffers to smooth operational continuity.

Payment and contracting considerations are also adapting, since higher input costs can impact pricing structures and the relative attractiveness of bundled service offerings. Therefore, commercial teams and health system purchasers are increasing the sophistication of total cost assessments, taking into account logistics, regulatory compliance, and potential duties. Ultimately, tariff-related pressures are accelerating strategic shifts toward supply-chain resilience, regional manufacturing partnerships, and contract designs that hedge against future trade-policy changes.

Segment-specific insights revealing how product types, user settings, technologies, distribution pathways, and clinical applications jointly dictate adoption dynamics

Insight into product segmentation reveals that the market is bifurcated between consumables and instruments, with consumables encompassing essential elements such as controls, kits, and reagents that determine assay performance and lot-to-lot consistency, while instruments include both benchtop analyzers suited for clinic and laboratory environments and handheld analyzers optimized for speed and portability. Shifts in purchasing behavior often prioritize total cost of ownership and the availability of validated consumable supplies, so manufacturers that secure long-term reagent supply and deliver intuitive instrument maintenance protocols gain a competitive edge.

From an end-user perspective, adoption patterns vary across clinics, diagnostic laboratories, home testing settings, and hospitals. Clinical decision workflows in hospital and large outpatient settings tend to demand higher throughput and integration with existing laboratory information systems, whereas clinics and home testing emphasize ease of use, minimal sample handling, and rapid result turnaround to support point-of-care consultations. Diagnostic laboratories continue to act as quality hubs, often validating and benchmarking point-of-care outputs to ensure method concordance and to support clinician confidence.

Technology segmentation further highlights the diversity of approaches to lipid measurement. Chromatographic methods and immunoassays offer high analytical specificity and are frequently used in centralized contexts, while colorimetric and enzymatic methods provide simpler, faster pathways to lipid quantification at the point of care. Each technology presents trade-offs among accuracy, cost, and operational complexity; therefore, product positioning must align with the clinical setting and the skill level of intended users.

Distribution channels also shape accessibility and adoption. Diagnostic laboratories, e-commerce platforms, hospital pharmacies, and retail pharmacies each play distinct roles in getting devices and consumables into clinical and consumer hands. E-commerce accelerates direct-to-consumer access and simplifies repeat consumable purchases, whereas hospital and retail pharmacies enable integration into institutional procurement and patient support programs. Finally, application-driven demand-spanning cardiovascular risk assessment, diabetes management, and preventive screening-frames clinical utility and the types of outcome data purchasers require for reimbursement and guideline adoption. Manufacturers that tailor solutions to these application needs and distribution realities can better align product development and commercialization efforts with end-user expectations.

A regional comparative analysis explaining how differing regulatory frameworks, infrastructure maturity, and payer landscapes influence point-of-care lipid testing trajectories

Regional dynamics shape both the adoption trajectory and operational strategies for point-of-care lipid testing. In the Americas, clinical networks emphasize rapid diagnostics integration into primary care and community clinics, supported by relatively mature reimbursement frameworks and a strong private-sector distribution system. These conditions encourage adoption of both benchtop and handheld analyzers that can demonstrate workflow efficiencies and improved patient engagement. Additionally, a robust base of diagnostic labs provides opportunities for hybrid deployment models where point-of-care platforms are validated against central laboratory reference methods.

Across Europe, the Middle East, and Africa, regulatory and reimbursement environments are heterogeneous, driving a more localized approach to market entry. In parts of Europe, well-established health technology assessment mechanisms prioritize clinical validation and cost-effectiveness evidence, which favors devices that can demonstrate quality and outcome benefits. Meanwhile, in the Middle East and Africa, infrastructure gaps and variability in laboratory capacity create demand for portable, easy-to-use devices and consumables that can operate with limited facilities and supply chain constraints. Manufacturers should therefore align regulatory strategies and support models with local health system needs, leveraging partnerships with regional distributors and clinical networks.

Asia-Pacific presents a mix of high-volume urban centers with advanced diagnostic infrastructure and expansive rural areas where decentralized testing can deliver substantial public health value. A strong manufacturing base in several countries supports both regional production and export opportunities, while rapid digital adoption facilitates remote monitoring and integration with national health initiatives. In this region, payers and providers are increasingly receptive to innovations that reduce clinical bottlenecks and enhance chronic disease management, making Asia-Pacific an important locus for scalable deployment and iterative product refinement.

How competitive advantage is being forged through assay innovation, integrated service models, strategic partnerships, and rigorous clinical evidence generation

Competitive dynamics in the point-of-care lipid testing space are defined by a mix of product innovation, strategic partnerships, and claims to clinical validation. Leading organizations invest heavily in assay development and usability engineering to differentiate through accuracy, speed, and integration capabilities. Supply-chain partnerships and co-development agreements with reagent and component suppliers are increasingly common as firms seek to secure raw materials and mitigate risk from trade-policy shifts.

In addition to technical differentiation, commercialization strategies vary widely. Some firms focus on comprehensive service offerings that bundle devices with consumables, training, and remote quality oversight, while others pursue a more modular approach that emphasizes low-cost consumables and broad distribution through e-commerce and pharmacy channels. Strategic alliances with healthcare networks, telehealth providers, and electronic health record vendors are shaping interoperability and care pathway alignment, which in turn influence purchasing decisions among health systems and clinics.

Regulatory compliance and evidence generation remain central to competitive advantage. Companies that prioritize robust clinical evaluation and establish clear pathways for regulatory clearance and post-market surveillance build trust with clinical stakeholders. Moreover, firms that demonstrate responsiveness to payer expectations-by generating real-world evidence of clinical utility in cardiovascular risk assessment, diabetes management, and preventive screening-can materially strengthen their market positioning. Ultimately, success hinges on marrying credible science with scalable commercial models and resilient supply chains.

Prioritized strategic actions for manufacturers and health system leaders to strengthen resilience, accelerate adoption, and demonstrate clinical and commercial value

Industry leaders should prioritize supply-chain diversification and manufacturing flexibility to hedge against trade-policy disruptions and component shortages. Investing in regional assembly hubs and qualifying alternate suppliers for critical reagents and instrument parts can materially reduce exposure to tariff and logistics volatility. At the same time, organizations should evaluate product designs that simplify component complexity, enabling more adaptable production footprints and faster regulatory updates when needed.

Second, companies must accelerate user-centric design and connectivity features for both benchtop and handheld analyzers to drive adoption in decentralized settings and the home. Streamlined workflows, integrated quality controls, and secure data transfer to electronic health records will differentiate offerings and support clinician acceptance. Complementing these technical improvements with structured training programs and remote technical support will reduce user errors and enhance clinical confidence.

Third, manufacturers should deepen engagement with payers, professional societies, and health systems to generate the clinical evidence required for guideline inclusion and reimbursement. Collaborative pilot programs that measure impact on clinical decision-making and downstream outcomes will strengthen value propositions. Parallel commercial strategies should explore bundled service models that combine device placement, consumable supply, and performance monitoring to simplify procurement and improve adherence.

Finally, pursue partnerships that extend beyond traditional distribution-linking with telehealth platforms, chronic care management vendors, and pharmacy networks-to create integrated care pathways. These alliances can expand reach, support patient retention for longitudinal monitoring, and create differentiated offerings that capture greater downstream value.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, device benchmarking, and expert validation to support strategic decision-making

This analysis synthesizes insights derived from a mixed-methods research approach that combines primary qualitative interviews with key industry stakeholders and systematic review of regulatory, clinical, and patent literature. Primary inputs included structured conversations with clinical laboratory directors, procurement leaders, device engineers, and payers to validate operational pain points and adoption criteria. These perspectives were triangulated with publicly available regulatory filings, clinical trial registries, and peer-reviewed publications to ensure technical and clinical accuracy.

Quantitative elements of the methodology comprised device performance benchmarking and comparative assessments of assay principles, focusing on analytical sensitivity, specificity, and user workflow metrics. Supply-chain and trade-policy analyses were informed by customs and tariff schedules, logistics reports, and manufacturer disclosures to capture cost and availability implications. Throughout the process, findings were reviewed by an external panel of clinical and technical experts to stress-test assumptions and identify blind spots.

Limitations of the research include variability in regional data transparency and differences in clinical practice patterns that can influence adoption scenarios. To mitigate these constraints, the methodology emphasizes qualitative contextualization and cross-validation across multiple independent sources. The result is a pragmatic, evidence-focused assessment intended to support strategic decision-making rather than deterministic market projections.

A concise synthesis highlighting the imperative for integrated product, clinical evidence, and supply-chain strategies to realize point-of-care lipid testing potential

Point-of-care lipid testing stands at an inflection point, propelled by technological improvements, a shift toward decentralized care, and evolving expectations from clinicians and patients. The interplay between instrument design, consumable reliability, and distribution strategies will determine which solutions scale effectively across diverse clinical settings. Concurrently, trade-policy shifts and supply-chain realities necessitate more resilient commercial models and pragmatic manufacturing choices.

For stakeholders across the value chain, the imperative is clear: align product development with real-world clinical workflows, invest in evidence generation that addresses payer and guideline requirements, and construct flexible supply chains that support continuity of care. By doing so, organizations can unlock the clinical and operational benefits of rapid lipid assessment while safeguarding quality and accessibility. Ultimately, the most successful players will be those that integrate robust science, user-centric design, and adaptive commercial strategies to meet the needs of an increasingly decentralized diagnostic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. POC Lipid Testing Market, by Product Type

  • 8.1. Consumables
    • 8.1.1. Controls
    • 8.1.2. Kits
    • 8.1.3. Reagents
  • 8.2. Instruments
    • 8.2.1. Benchtop Analyzers
    • 8.2.2. Handheld Analyzers

9. POC Lipid Testing Market, by Technology

  • 9.1. Chromatographic Methods
  • 9.2. Colorimetric Methods
  • 9.3. Enzymatic Methods
  • 9.4. Immunoassays

10. POC Lipid Testing Market, by Application

  • 10.1. Cvd Risk Assessment
  • 10.2. Diabetes Management
  • 10.3. Preventive Screening

11. POC Lipid Testing Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Labs
  • 11.3. Home Testing
  • 11.4. Hospitals

12. POC Lipid Testing Market, by Distribution Channel

  • 12.1. Diagnostic Laboratories
  • 12.2. E-commerce
  • 12.3. Hospital Pharmacies
  • 12.4. Retail Pharmacies

13. POC Lipid Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. POC Lipid Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. POC Lipid Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States POC Lipid Testing Market

17. China POC Lipid Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. A. Menarini Industrie Farmaceutiche Riunite S.r.l.
  • 18.6. Abaxis, Inc. by Zoetis Inc
  • 18.7. Abbott Laboratories
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. bioMerieux SA
  • 18.10. Callegari Srl
  • 18.11. Chembio Diagnostic Systems, Inc. by BIOSYNEX SA
  • 18.12. Danaher Corporation
  • 18.13. EKF Diagnostics Holdings plc
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. General Life Biotechnology Co., Ltd.
  • 18.16. Helena Laboratories Corporation
  • 18.17. Nova Biomedical
  • 18.18. Quidel Corporation
  • 18.19. SD Biosensor, Inc.
  • 18.20. Sekisui Medical Co., Ltd.
  • 18.21. Siemens AG
  • 18.22. Sienco, Inc.
  • 18.23. Sinocare Inc.
  • 18.24. Thermo Fisher Scientific Inc.
  • 18.25. Trinity Biotech PLC
  • 18.26. VivaChek Biotech (Hangzhou) Co., Ltd.
  • 18.27. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POC LIPID TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POC LIPID TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 152. GCC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. G7 POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. NATO POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NATO POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)